cefditoren pivoxil
SPECTRACEF (cefditoren pivoxil) is clinical pharmacology pharmacokinetics absorption oral bioavailability following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Approved for mild to moderate infections in adults, adolescents (12 years of age, older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. First approved in 2001.
Drug data last refreshed 22h ago · AI intelligence enriched 2mo ago
SPECTRACEF (cefditoren pivoxil) is an oral third-generation cephalosporin antibiotic that treats mild to moderate bacterial infections in adults and adolescents 12 years and older. It works by inhibiting bacterial cell wall synthesis after oral absorption and hydrolysis to active cefditoren. The drug achieves optimal plasma concentrations when taken with food, particularly high-fat meals, which increase bioavailability by up to 70%.
Product is approaching loss of exclusivity with stable competitive pressure (30% intensity), indicating potential team downsizing or transition planning within the next 1-2 years.
CLINICAL PHARMACOLOGY Pharmacokinetics Absorption Oral Bioavailability Following oral administration, cefditoren pivoxil is absorbed from the gastrointestinal tract and hydrolyzed to cefditoren by esterases. Maximal plasma concentrations (C max ) of cefditoren under fasting conditions average 1.8 ±…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SPECTRACEF offers limited career growth opportunities as a mature, LOE-approaching product with zero linked job postings. Roles available are primarily focused on maintaining market position, managing generic transition, and optimizing profitability rather than launching or expanding market share.